ShareSpot

  • The LATITUDE to Stay On Track: NIH to Launch Study in People Non-Adherent to Daily Treatment

    Karin L. Klingman's picture

    Taking effective HIV medications as prescribed offers many benefits for people living with HIV—life expectancy normalizes and viral loads drop below detectable levels, preventing the risk of sexual transmission in those who achieve and maintain durable viral suppression. Unfortunately, many...

  • Short Bites: The Association between Oral Disease and Type of Antiretroviral Therapy among Perinatally HIV-Infected Youth

    Antiretroviral therapy (ART) has been very successful at preserving immune function and controlling opportunistic infections among individuals infected with HIV. Oral mucosal diseases associated with advanced immunosuppression, including candidiasis and hairy leukoplakia, are significantly less...

  • AETCs at the 2018 Ryan White Conference

    Judy Collins's picture

    The AETC Program will be well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. Additionally, the AETC National Coordinating Resource Center will be exhibiting an array of AETC Program developed resources and promotional items at Booth #12 in...

  • Sexual Assault: PEP is an Urgent Health Need

    When a patient presents to your emergency department, urgent care or clinic with a chief complaint of sexual assault within the last 24 hours, the challenge is recognizing that, along with safety and criminal justice concerns, this patient has emergent health needs. One of the most urgent of...

  • Rapid ART Start

    Susa Coffey's picture

    The International AIDS Society (IAS)-USA recently released its 2018 HIV treatment and prevention recommendations. The document is particularly notable for its discussion of "When to Start ART."

    The IAS-USA recommends "rapid" or immediate start of ART...

  • Doravirine--New NNRTI Approved by FDA

    Susa Coffey's picture

    The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48...

  • Short Bites: HIV in the Southeast United States

    Southern states today account for an estimated 44 percent of all people living with an HIV diagnosis in the U.S.,[1] despite having only about one-third (37%) of the overall U.S. population. Diagnosis rates for people in the South are higher than for Americans overall. Eight of the 10 states...

  • Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects

    Jennifer Cocohoba's picture

    Integrase inhibitors have become primary treatment for most people living with HIV; however, the impact of newer integrase inhibitors on pregnancy outcomes has not been well described. Researchers for the observational Tsepamo study have been examining birth outcomes in Botswanan...

  • Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy

    Jennifer Cocohoba's picture

    Although DTG currently is not a desirable medication for women to take pre-conception (see Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects), findings from the DolPHIN study suggest that it may be a very useful agent for women who start ART during...

  • Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women

    Jennifer Cocohoba's picture

    Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.

    The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43...

  • TargetHIV: New Name, New Look

    Nicolé H. Mandel's picture

    It's easier than ever to stay on target. The Health Resources and Services Administration's (HRSA) Ryan White HIV/AIDS Program (RWHAP) technical assistance (TA) and training website has undergone a major update to make it easier for users to access tools and materials for the RWHAP. The website...

  • Dolutegravir + 3TC in Initial Therapy

    Susa Coffey's picture

    As we have commented in the past, initial ARV regimens consisting of 2 drugs tend to perform poorly in comparison with currently recommended 3-drug regimens. Yet, given toxicity concerns about some ARVs (particularly about tenofovir DF and abacavir) and cost concerns about 3-drug regimens, the...

  • U=U in PARTNER2 Study of MSM

    Susa Coffey's picture

    PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).

    PARTNER1 evaluated HIV...

  • Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study

    Susa Coffey's picture

    The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with...

  • Practicing Cultural Humility to Transform Health Care

    Jennifer McGee-Avila's picture
    Moving beyond culture competency to cultural humility acknowledges patients’ authority over their own lived experience

    Health care delivery often involves a one-size-fits-all approach. As clinicians, we treat a patient with a particular diagnosis similar to the last patient we saw with the same...

  • Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects

    Susa Coffey's picture

    On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...

  • Bictegravir/TAF/FTC in Women

    Susa Coffey's picture

    The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC), recently approved by the FDA, has been shown in four Phase III trials to be effective as initial therapy and as a switch regimen in patients with stably suppressed HIV RNA...

  • Immediate ART Initiation Improves Time to Viral Suppression

    Susa Coffey's picture

    The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits. Based on randomized clinical trials done in developing-world settings, the...

  • Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study

    Susa Coffey's picture

    The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing...

  • Naltrexone Improves Virologic Suppression

    Susa Coffey's picture

    Release from correctional settings is a high-stakes time for persons with HIV, as it is for those with other health issues. People with substance use disorders often relapse, and those with HIV often stop ART and do not engage in HIV care, increasing the risk of declines in...